公开(公告)号：US20250057862A1

公开(公告)日：2025-02-20

申请号：US18720169

申请日：2022-12-15

Applicant: LifeScience AS

Inventor： Jan Remmereit ,  Trond-inge Kvernevik

IPC: A61K31/7012 ,  A23K10/22 ,  A23K10/30 ,  A23K20/158 ,  A23K20/163 ,  A23K50/80 ,  A61P31/14 ,  A61P33/14

Abstract: The present invention relates to the use of compositions comprising sialic acid to improve the health of fish in aquaculture, and in particular to inhibit or treat viral infections in fish, improve growth, and to inhibit or treat infestation of fish with sea lice.

公开(公告)号：US20240209067A1

公开(公告)日：2024-06-27

申请号：US18425919

申请日：2024-01-29

Applicant: MEDIMMUNE, LLC ,  HUMABS BIOMED SA

Inventor： Ebony BENJAMIN ,  Nicole KALLEWAARD-LELAY ,  Josephine Mary MCAULIFFE ,  Frances PALMER-HILL ,  Leslie WACHTER ,  Andy YUAN ,  Qing ZHU ,  Davide CORTI ,  Antonio LANZAVECCHIA ,  Barbara GUARINO ,  Anna DEMARCO

IPC: C07K16/10 ,  A61K31/13 ,  A61K31/215 ,  A61K31/7012 ,  A61K39/00 ,  A61K39/395 ,  A61K39/42 ,  A61K45/06 ,  C12P21/00 ,  G01N33/569 ,  G01N33/577

CPC classification number: C07K16/1018 ,  A61K31/13 ,  A61K31/215 ,  A61K31/7012 ,  A61K39/3955 ,  A61K39/42 ,  A61K45/06 ,  C12P21/005 ,  G01N33/56983 ,  G01N33/577 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/11

Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.

公开(公告)号：US12016925B2

公开(公告)日：2024-06-25

申请号：US17666529

申请日：2022-02-07

Applicant: Medgaea Japan Co., Ltd. ,  Medgaea Life Sciences Ltd.

Inventor： Chang-Jer Wu ,  Bo-Rui Chen ,  Chih-Chun Hong ,  Yuh-Ting Huang ,  Masahiko Iha ,  Makoto Tomori

IPC: A61K47/26 ,  A61K31/573 ,  A61K31/7004 ,  A61K31/7012 ,  A61P17/00

CPC classification number: A61K47/26 ,  A61K31/573 ,  A61K31/7004 ,  A61K31/7012 ,  A61P17/00

Abstract: A carbohydrate composition includes fucose, glucuronic acid, galactose, and arabinose. Based on the total weight of the carbohydrate composition, the content of fucose is 45.5% to 76% by weight; the content of glucuronic acid is 11% to 19% by weight; the content of galactose is 4.5% to 14.5% by weight, and the content of arabinose is 5.5% to 18% by weight. A pharmaceutical ingredient including the above-mentioned carbohydrate composition is provided.

公开(公告)号：US11932682B2

公开(公告)日：2024-03-19

申请号：US17507482

申请日：2021-10-21

Applicant: MEDIMMUNE, LLC ,  HUMABS BIOMED SA

Inventor： Ebony Benjamin ,  Nicole Kallewaard-LeLay ,  Josephine Mary McAuliffe ,  Frances Palmer-Hill ,  Leslie Wachter ,  Andy Yuan ,  Qing Zhu ,  Davide Corti ,  Antonio Lanzavecchia ,  Barbara Guarino ,  Anna DeMarco

IPC: A61K31/13 ,  A61K31/215 ,  A61K31/7012 ,  A61K39/395 ,  A61K39/42 ,  A61K45/06 ,  C07K16/10 ,  C12P21/00 ,  G01N33/569 ,  G01N33/577 ,  A61K39/00

CPC classification number: C07K16/1018 ,  A61K31/13 ,  A61K31/215 ,  A61K31/7012 ,  A61K39/3955 ,  A61K39/42 ,  A61K45/06 ,  C12P21/005 ,  G01N33/56983 ,  G01N33/577 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/11 ,  A61K39/3955 ,  A61K2300/00 ,  A61K31/215 ,  A61K2300/00 ,  A61K31/7012 ,  A61K2300/00 ,  A61K31/13 ,  A61K2300/00

Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.

公开(公告)号：US11813271B2

公开(公告)日：2023-11-14

申请号：US17916104

申请日：2021-03-31

Applicant: LifeScience AS

Inventor： Jan Remmereit

IPC: A61K31/7012 ,  A61P31/14

CPC classification number: A61K31/7012 ,  A61P31/14

Abstract: The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).

公开(公告)号：US20220088046A1

公开(公告)日：2022-03-24

申请号：US17478185

申请日：2021-09-17

Applicant: MVRIX Co., Ltd.

Inventor： Woo Jae Chung ,  Dae Hyuk Kweon ,  Jinhyo Chung ,  Caleb Hong

IPC: A61K31/7012 ,  A61K47/54 ,  A61P31/12

Abstract: Disclosed is a viral receptor that contains a sialic acid compound at one side thereof to provide binding affinity to a virus, and contains a lipid at the other side thereof, and that can be widely used for the treatment of viral infections based on this characteristic.

公开(公告)号：US20220031720A1

公开(公告)日：2022-02-03

申请号：US17296504

申请日：2019-11-21

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Vered PADLER-KARAVANI ,  Eliran Moshe REUVEN ,  Shani LEVIATAN BEN-ARYE

IPC: A61K31/7012 ,  A61K9/127 ,  A61K39/39 ,  A61K39/00 ,  A61P35/00 ,  A61K39/395

Abstract: The present invention provides an active cancer vaccine and specifically an immunogenic compositions of membrane vesicles that serve as biomimetic nanoparticles derived from eukaryotic cell membranes that bear N-glycolylneuraminic acid glycoconjugates. These compositions can elicit beneficial immunological responses for treatment of Neu5Gc-positive tumors. The present invention provides methods of generating and using Neu5Gc-conjugated nanoparticles from eukaryotic cells membranes designated nano-ghosts.

公开(公告)号：US20210340214A1

公开(公告)日：2021-11-04

申请号：US17271792

申请日：2019-08-28

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Sandeep P. INAMDAR ,  Kristen PIERCE ,  Hong XIANG ,  Susannah D. BARBEE

IPC: C07K14/705 ,  A61P35/00 ,  A61K9/00 ,  A61K31/7012 ,  C07K16/18

Abstract: The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1) to a subject in need thereof, for example, a cancer patient.

公开(公告)号：US20210252031A1

公开(公告)日：2021-08-19

申请号：US17306614

申请日：2021-05-03

Applicant: Curemark, LLC

Inventor： Joan M. Fallon ,  Richard Feltenstein

IPC: A61K31/7016 ,  A61K31/045 ,  A61K31/7012 ,  A61K31/047

Abstract: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

公开(公告)号：US20210220378A1

公开(公告)日：2021-07-22

申请号：US16755410

申请日：2018-10-11

Applicant: LifeScience AS

Inventor： Jan Remmereit ,  Hogne Vik

IPC: A61K31/7012 ,  A61K9/00 ,  A61K9/08 ,  A61P31/16 ,  A61P11/02 ,  A61M11/00 ,  A61K47/10 ,  A61K47/36

Abstract: The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NANA are provided for treating or preventing viral infections, such as those causing the common cold.